Literature DB >> 16794795

cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma.

Osamu Takata1, Yutaka J Kawamura, Fumio Konishi, Junichi Sasaki, Toshihiro Kai, Yasuyuki Miyakura, Hideo Nagai, Toshihiko Tsukamoto.   

Abstract

PURPOSE: Distant metastasis is a significant prognostic factor of colon carcinoma. Adjuvant chemotherapy has been shown to decrease its recurrence. However, there are no definitive methods for the diagnosis of hepatic recurrence after potentially curative surgery. The aim of this study was to evaluate the accuracy of mRNA expression profiling using samples obtained from primary tumors to predict hepatic recurrence.
METHODS: Patients with stage III colorectal carcinoma without any recurrence for at least 5 years (group A: n = 9) and patients with stage IV carcinoma with hepatic metastasis (group B: n = 10) were included in this study. Tissue samples were collected from the primary tumor and adjacent normal colonic mucosa at the time of surgery in each patient. Total RNA was extracted and the mRNA expression profile was examined using a cDNA macroarray.
RESULTS: A hierarchical clustering analysis revealed a dendrogram in which the patients were divided into two clusters. One cluster consisted of seven patients in group A and two in group B. The other consisted of two patients in group A and eight in group B. Therefore, the positive and negative predictive value of hierarchical clustering analysis for hepatic metastasis was 80.0% and 78.8%, respectively. Fifteen genes were revealed to be upregulated and 12 were downregulated in group B. The upregulated genes included CCNA2, TP53, and MDM2, while the downregulated genes included CDH1, GADD45A, and BCL2L2.
CONCLUSIONS: mRNA expression profiling by a cDNA array analysis of specimens obtained from primary tumors was found to be useful for distinguishing patients with and without hepatic metastasis. This method is expected to contribute to the identification of patients at high risk for hepatic recurrence, while also helping in the administration of intensive adjuvant chemotherapy for such high risk patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794795     DOI: 10.1007/s00595-006-3210-0

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  28 in total

Review 1.  DNA microarrays: a new diagnostic tool and its implications in colorectal cancer.

Authors:  C Stremmel; A Wein; W Hohenberger; B Reingruber
Journal:  Int J Colorectal Dis       Date:  2002-05       Impact factor: 2.571

2.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

3.  Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia.

Authors:  O Kitahara; Y Furukawa; T Tanaka; C Kihara; K Ono; R Yanagawa; M E Nita; T Takagi; Y Nakamura; T Tsunoda
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma.

Authors:  Y Kitadai; L M Ellis; S L Tucker; G F Greene; C D Bucana; K R Cleary; Y Takahashi; E Tahara; I J Fidler
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

5.  Quantitative monitoring of gene expression patterns with a complementary DNA microarray.

Authors:  M Schena; D Shalon; R W Davis; P O Brown
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

6.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

7.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

8.  Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.

Authors:  K Sumpter; C Harper-Wynne; D Cunningham; A Gillbanks; A R Norman; M Hill
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-08       Impact factor: 4.126

9.  A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.

Authors:  David P Ryan; Jeffrey W Clark; Matthew H Kulke; Charles S Fuchs; Craig C Earle; Peter C Enzinger; Keith Stuart; Keith J Catarius; Jennifer Winkelmann; Robert J Mayer
Journal:  Cancer Invest       Date:  2003       Impact factor: 2.176

10.  Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.

Authors:  Javier Cassinello; Pilar Escudero; Antonieta Salud; Fernando Marcos; Eduardo Pujol; Ramón Pérez-Carrión; Antonio Colmenarejo; Ricardo González del Val; José Valero; Mauro J Oruezábal; Vicente Guillem; Inés García; Alberto Arcediano; Xavier Marfà
Journal:  Clin Colorectal Cancer       Date:  2003-08       Impact factor: 4.481

View more
  4 in total

1.  Different incidence of synchronous liver metastasis between proximal and distal colon cancer.

Authors:  Daisuke Yoshida; Yoichi Ikeda; Keiichiro Waki; Ken Shirabe; Yoshihiro Kakeji; Shunichi Tsujitani; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-11-18       Impact factor: 2.549

2.  Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance.

Authors:  Christina M Medina-Ramirez; Sumanta Goswami; Tatiana Smirnova; Daniel Bamira; Benjamin Benson; Neal Ferrick; Jeffrey Segall; Jeffrey W Pollard; Richard N Kitsis
Journal:  Cancer Res       Date:  2011-10-28       Impact factor: 12.701

3.  Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism.

Authors:  Beatriz Carvalho; Anke H Sillars-Hardebol; Cindy Postma; Sandra Mongera; Jochim Terhaar Sive Droste; Askar Obulkasim; Mark van de Wiel; Wim van Criekinge; Bauke Ylstra; Remond J A Fijneman; Gerrit A Meijer
Journal:  Cell Oncol (Dordr)       Date:  2012-01-26       Impact factor: 6.730

4.  Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker.

Authors:  Albert Y Lin; Mei-Sze Chua; Yoon-La Choi; William Yeh; Young H Kim; Raymond Azzi; Gregg A Adams; Kristin Sainani; Matt van de Rijn; Samuel K So; Jonathan R Pollack
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.